CHKA Enzyme Drives Diabetic Blood Vessel Damage Through NAD+ Pathway
New research identifies choline kinase alpha as a key driver of diabetic retinopathy and microvascular dysfunction.
Summary
Researchers used single-cell sequencing to identify three distinct endothelial cell populations in diabetic retinas. They discovered that choline kinase alpha (CHKA) is highly expressed in one subpopulation associated with pathological blood vessel growth. When CHKA was silenced, it reduced harmful angiogenesis and improved retinal vascular function in diabetic mice. The enzyme works through the NAD+-SIRT1-Notch signaling pathway, and supplementing with NMN (a NAD+ precursor) partially reversed CHKA silencing effects. Clinical samples and genetic studies confirmed CHKA's role in diabetic complications, suggesting it could be a therapeutic target.
Detailed Summary
Diabetic retinopathy affects millions worldwide and serves as a model for understanding how diabetes damages blood vessels throughout the body. This groundbreaking study used single-cell RNA sequencing to map the cellular landscape of diabetic retinas and identify why certain blood vessels become dysfunctional.
Researchers analyzed retinal tissue from diabetic and healthy mice, identifying three distinct endothelial cell subpopulations. One subcluster showed elevated expression of choline kinase alpha (CHKA), an enzyme involved in cell membrane metabolism, and was strongly associated with pathological angiogenesis - the harmful growth of new blood vessels characteristic of diabetic retinopathy.
When scientists silenced CHKA in laboratory studies, they observed dramatic reductions in angiogenic activity and improved vascular function in diabetic mouse models. The mechanism involves CHKA's regulation of NAD+ metabolism - silencing CHKA reduced NAD+ levels, which affected the SIRT1-Notch signaling pathway crucial for blood vessel development. Importantly, supplementing with nicotinamide mononucleotide (NMN), a NAD+ precursor already popular in longevity circles, partially reversed the anti-angiogenic effects.
The clinical relevance was validated through analysis of human samples and Mendelian randomization studies, which provided strong genetic evidence linking increased CHKA expression with diabetic microvascular complications across multiple organs. This suggests CHKA's role extends beyond the eye to affect kidney, heart, and peripheral blood vessels.
These findings offer a new therapeutic target for diabetic complications. Unlike current treatments that broadly suppress blood vessel growth, targeting CHKA could provide more precise intervention by addressing the specific endothelial subpopulation driving pathological changes while preserving healthy vascular function.
Key Findings
- CHKA enzyme is highly expressed in specific endothelial cells driving diabetic blood vessel damage
- Silencing CHKA reduced pathological angiogenesis and improved vascular function in diabetic mice
- CHKA regulates blood vessel dysfunction through NAD+-SIRT1-Notch signaling pathway
- NMN supplementation partially reversed anti-angiogenic effects of CHKA silencing
- Clinical and genetic studies confirm CHKA's role in human diabetic complications
Methodology
Single-cell RNA sequencing of diabetic and control mouse retinas identified endothelial subpopulations. Functional studies used CHKA silencing in cell culture and diabetic mouse models, with validation through clinical samples and Mendelian randomization analysis.
Study Limitations
Study was primarily conducted in mouse models with limited human validation. The therapeutic potential of targeting CHKA requires further clinical investigation, and optimal dosing strategies for NAD+ supplementation remain unclear.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.